[C:1]([C:5]1[CH:10]=[CH:9][C:8]([N:11]2[C:15](=[O:16])[C:14]([CH3:18])([CH3:17])[N:13]([CH2:19][C:20]3[CH:25]=[CH:24][N:23]=[C:22](Cl)[CH:21]=3)[C:12]2=[O:27])=[CH:7][CH:6]=1)([CH3:4])([CH3:3])[CH3:2].[CH:28]1([NH2:31])[CH2:30][CH2:29]1>>[C:1]([C:5]1[CH:10]=[CH:9][C:8]([N:11]2[C:15](=[O:16])[C:14]([CH3:18])([CH3:17])[N:13]([CH2:19][C:20]3[CH:25]=[CH:24][N:23]=[C:22]([NH:31][CH:28]4[CH2:30][CH2:29]4)[CH:21]=3)[C:12]2=[O:27])=[CH:7][CH:6]=1)([CH3:4])([CH3:3])[CH3:2]A suspension of 0.6 g of 3-(4-tert-butylphenyl)-1-[(2-chloropyridin-4-yl)methyl]-5,5-dimethylimidazolidine-2,4-dione obtained in stage a) of Example 7 in 1.1 mL of cyclopropylamine is heated by microwave at 150° C. for 6 hours and then concentrated under reduced pressure. The residue is purified by chromatography on a column of silica, eluting with a mixture of petroleum ether and ethyl acetate (50/50 by volume) to give 48 mg of 3-(4-tert-butylphenyl)-1-{[2-(cyclopropylamino)pyridin-4-yl]methyl}-5,5-dimethylimidazolidine-2,4-dione, the characteristics of which are as follows: